Late-Breaking Sessions

AACC has added the following late-breaking sessions to the scientific meeting schedule on hepatitis C, disruptive technology, Zika, and interventional gene therapy.

Hepatitis C Virus

This three-session hepatitis C scientific track will take place on Monday, August 1.

Hepatitis C Virus (HCV)—Research in Treatment and Prevention 32105

This session will provide an overview of issues related to the hepatitis C virus (HCV), including challenges in treatment, global health implications, and opportunities for research. Additional focus will be given in particular to research in HCV vaccines, and how that may impact the spread of HCV as well as current treatment paradigms. Attendees will hear about recent scientific advances for detection and treatment of HCV. This is Part 1 of a three-part scientific track invited by the Annual Meeting Organizing Committee.

Hepatitis C: Unique Challenges, Successes, and Opportunities
Stuart Ray, MD, Johns Hopkins University School of Medicine

HCV Vaccines: Current Status and Future Directions
Justin Bailey, Johns Hopkins University School of Medicine

Debate: Is Hepatitis C of Continuing Concern, or Is It Going Away? 32409

This session will provide a discussion of the impact of current treatment modalities on the efforts to eradicate HCV. This issue of whether these strategies will be effective, and whether HCV will continue to be a global health problem will be debated by the speakers in this session. After presenting each side of the issue, there will be a Q&A session including the audience and an open discussion based upon the points presented by each of the speakers. This is Part 2 of a three-part scientific track invited by the Annual Meeting Organizing Committee.

In the Modern Era of DAAs, HCV Is a Vanishing Problem – Pro
Kimberly Page, PhD, MPH, MS, University of New Mexico Health Sciences Center

In the Modern Era of DAAs, HCV Is Not a Vanishing Problem – Con
Camilla Graham, MD, Harvard Medical School

HCV and Laboratory Medicine: Testing in Support of Screening and Diagnosis 32218

This session will provide a discussion of the various tools available for in vitro diagnostic HCV testing for use in patient care. The speakers will address testing for both screening and confirmation of diagnosis, as well as testing in support of therapeutic interventions. Attendees will hear about pertinent issues for laboratory medicine in the context of HCV infected patients. This is Part 3 of a three-part scientific track invited by the Annual Meeting Organizing Committee.

The HCV Diagnostic Toolbox
William Osburn, PhD, Johns Hopkins University School of Medicine

The Changing Landscape of Testing for HCV
Arthur Kim, MD, Harvard Medical School

Disruptive Technology

This two-part session will take place on Monday, August 1.

Technologies That Could Change the Future of the Clinical Laboratory, Part 1 and Part 2 32421 and 32220

This session focuses on technologies that are likely to positively disrupt the way diagnostic tests in the clinical laboratory are performed and transported. The topics will include emerging RT-PCR technology that will allow analyses in less than one minute to enable point-of-care nucleic acid testing; microfluidic sample processing integrated to high pressure mass spectrometry for chip-based analyses; alternative sampling techniques for analysis of blood that will challenge the existing phlebotomy paradigm; and drone transportation of laboratory samples to allow access to clinical laboratory testing in remote areas.

Part 1 (32421)

Technologies That Could Change the Future of the Clinical Laboratory
Carl Wittwer, MD, PhD, University of Utah
J. Michael Ramsey, The University of North Carolina at Chapel Hill

Part 2 (32220)

Drone Transportation of Chemistry, Hematology, Coagulation, and Microbiological Samples: Promises and Possibilities
Timothy Amukele, PhD, MD, Johns Hopkins University

Alternative Sampling Technologies: Beyond Venous Phlebotomy
James Nichols, PhD, Vanderbilt University Medical Center

Zika Virus

This session will take place on Tuesday, August 2.

Zika Virus – Global Impact and the Role of Diagnostic Testing 33122

This session will provide an overview of Zika virus, its disease manifestations, and appropriate diagnostic tests. Treatment and detection strategies will be discussed, along with important issues related to diagnostic testing. Additionally, important regulatory issues regarding accelerated review for emergency use authorization by the Food and Drug Administration will be discussed.

Diagnostics for Zika in the Americas: Unique Challenges and Considerations
Randall Kincaid, PhD, National Institute of Allergy and Infectious Diseases

U.S. FDA Emergency Use Authorization: Submission requirements for Zika Assays
Stephen Lovell, PhD, Center for Devices and Radiological Health, Food and Drug Administration

Rapid, Low-Cost Detection of Zika Virus Using Programmable Biomolecular Components
Keith Pardee, PhD, University of Toronto

Interventional Gene Therapy

This session will take place on Wednesday, August 3.

Correcting Nature’s Mistakes and Beyond: The Promise of Gene Therapy 34103

This session will provide a discussion of the current research applications of gene editing and their potential for development of therapeutic interventions. Attendees will hear how about different techniques for gene modification, and how these may be used for the treatment of disease.

Immunotherapy of Cancer Using Genetically-Enhanced T Cells
Michael Milone, MD, PhD, Hospital of the University of Pennsylvania

Adeno-Associated Virus (AAV)-based Gene Therapy of Genetic Disease
Valder Arruda, MD, PhD, Children’s Hospital of Philadelphia

Gene Editing for the Treatment of Genetic Disease
Matthew Porteus, MD, PhD, Stanford University